Acadia Pharmaceuticals has become one of the most highly valued biomedical companies in San Diego largely on the promise of an experimental drug for psychosis.
Next year, the 21-year-old company expects to begin delivering on that promise.
Sometime in the first quarter of 2015, Acadia plans to submit a marketing application for its medication Nuplazid. The drug, also known by its generic name of pimavanserin, has successfully completed Phase 3 testing for Parkinson’s disease psychosis. It’s in Phase 2 clinical trials for schizophrenia and Alzheimer’s disease psychosis.
Together, these conditions represent a huge population of patients — and thus a potentially huge pharmaceutical market.
Acadia, with a stock value of more than $3.2 billion, has gained a following among investors and stock analysts who believe Nuplazid will succeed. Shares of Acadia closed Tuesday at $30.17, down 6.4 percent for the day and up 21 percent for the year.
Seriously, how many ■■■■■■■ meds and billions do they have to produce till the ■■■■■■■ are satisfied? All this med thing is a ■■■■■■■ jungle of evil and greed. Pisses me off when a new “Wonderdrug!” is being ■■■■ out on the market every ■■■■■■■ day.
When a med for schizophrenia goes through and is approved, it is then usually approved for bipolar.
There are differences, but many similarities - these 2 illnesses/disorders are not as different as once thought
and almost every topic on this disease that doesnt look at it from a medicical pov gets shut down immediately. i thought it was a forum for sz’s and not the “concerning public” who are clueless
15